HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Comparison of acute toxicities associated with cetuximab-based bioradiotherapy and platinum-based chemoradiotherapy for head and neck squamous cell carcinomas : A single-institution retrospective study in Japan

Files in This Item:
manuscript.pdf831.56 kBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/62577

Title: Comparison of acute toxicities associated with cetuximab-based bioradiotherapy and platinum-based chemoradiotherapy for head and neck squamous cell carcinomas : A single-institution retrospective study in Japan
Authors: Sakashita, Tomohiro Browse this author →KAKEN DB
Homma, Akihiro Browse this author →KAKEN DB
Hatakeyama, Hiromitsu Browse this author →KAKEN DB
Furusawa, Jun Browse this author
Kano, Satoshi Browse this author →KAKEN DB
Mizumachi, Takatsugu Browse this author →KAKEN DB
Iizuka, Satoshi Browse this author
Onimaru, Rikiya Browse this author →KAKEN DB
Tsuchiya, Kazuhiko Browse this author →KAKEN DB
Yasuda, Koichi Browse this author →KAKEN DB
Shirato, Hiroki Browse this author →KAKEN DB
Fukuda, Satoshi Browse this author →KAKEN DB
Keywords: mucositis
dermatitis
cisplatin
radiotherapy
chemotherapy
molecular target therapy
Issue Date: Aug-2015
Publisher: Taylor & Francis
Journal Title: Acta Oto-laryngologica
Volume: 135
Issue: 8
Start Page: 853
End Page: 858
Publisher DOI: 10.3109/00016489.2015.1030772
PMID: 25814008
Abstract: Conclusion: Grade ≥ 3 mucositis/stomatitis and inability to feed orally were problematic for patients undergoing cetuximab-based bioradiotherapy (BRT) as well as platinum-based chemoradiotherapy (CRT). Severe mucositis/stomatitis and radiation dermatitis should be addressed carefully in patients undergoing cetuximab-based BRT as well. Objectives: The efficacy of cetuximab-based BRT in locally advanced head and neck squamous cell carcinomas has been established. However, the safety of cetuximab-based BRT in comparison with platinum-based CRT is currently under investigation. Method: This study retrospectively analyzed 14 patients undergoing cetuximab-based BRT and 29 patients undergoing platinum-based CRT to compare the incidence of acute toxicities. In the BRT group, an initial cetuximab loading dose of 400 mg/m2 was delivered 1 week before the start of radiotherapy. Seven weekly infusions of 250 mg/m2 of cetuximab followed during the definitive radiotherapy. In the CRT group, cisplatin was administered at a dose of 40 mg/m2 weekly during the definitive radiotherapy. Results: The BRT group had a higher incidence of Grade ≥ 3 radiation dermatitis than did the CRT group (43% vs 3%, respectively, p < 0.01). The incidence rate of Grade ≥ 3 mucositis/stomatitis was 64.3% and 41.4% in the BRT and CRT group, respectively (p = 0.1484), while the incidence rate of the inability to feed orally was 38.5% and 55.2%, respectively (p = 0.2053).
Rights: This is an Accepted Manuscript of an article published by Taylor & Francis in Acta Oto-Laryngologica on 2015, available online: http://www.tandfonline.com/10.3109/00016489.2015.1030772
Type: article (author version)
URI: http://hdl.handle.net/2115/62577
Appears in Collections:国際連携研究教育局 : GI-CoRE (Global Institution for Collaborative Research and Education : GI-CoRE) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 坂下 智博

Export metadata:


 

Feedback - Hokkaido University